Skip to content

Effect of pre-injection of alfentanil on remazolam induction of gynecological day surgery

Effect of pre-injection of alfentanil on remazolam induction of gynecological day surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075911
Enrollment
Unknown
Registered
2023-09-19
Start date
2023-10-01
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:Affentanil 5ug/kg

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Gynecological patients who are scheduled to undergo hysteroscopy under total intravenous anesthesia; 2. ASA I-II grade; 3. BMI 18-28; 4. Aged 18-65 years.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to any ingredients such as benzodiazepine opioids propofol and micuramide; 2. Patients with schizophrenia and severe depression; 3. Acute upper respiratory tract infection; 4. Poorly controlled severe hypertension; 5. History of alcohol abuse and long-term use of sedative analgesics and history of allergies; 6. Markov airway classification grade IV, those who require awake tracheal intubation as determined by the investigator; 7. Breastfeeding period female; 8. Other circumstances determined by the researcher to be unsuitable for selection; 9. The operation time is more than 1 hour; 10. Patients who have been hospitalized for more than 24 hours; 11. Patients who have been dropped out after surgery.

Design outcomes

Primary

MeasureTime frame
Time to induction of anesthesia;

Secondary

MeasureTime frame
Changes in hemodynamics at different times;Intraoperative BIS indicators;Dosage of alphandanil during the induction phase;Incidence of adverse reactions;

Countries

China

Contacts

Public ContactJi Fanceng

Weifang People's Hospital

jifanceng@163.com+86 135 6369 8838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026